Table 1b:
Patient Characteristics for Single Ventricle vs. Biventricular CHD Patients (n=108). Pedimacs Patients, September 19, 2012 to June 30, 2017
| Baseline Characteristics | Single Ventricle CHD (n=63) |
Biventricular CHD (n=45) |
p-value |
|---|---|---|---|
| Age (y) | 3.8 +/− 4.6 (n= 63) | 8.4 +/− 6.2 (n= 45) | <.0001 |
| Age (y) | 0.0005 | ||
| < 1 | 26 (41.3) | 9 (20.0) | |
| 1-5 | 22 (34.9) | 9 (20.0) | |
| 6-10 | 10 (15.9) | 10 (22.2) | |
| 11-19 | 5 (7.9) | 17 (37.8) | |
| Female | 24 (38.1) | 13 (28.9) | 0.3 |
| Race | 0.3 | ||
| White | 33 (52.4) | 30 (66.7) | |
| African American | 15 (23.8) | 7 (15.6) | |
| Other | 15 (23.8) | 8 (17.8) | |
| Body Surface Area (m2) | 0.6 +/− 0.4 (n= 61) | 1.0 +/− 0.6 (n= 45) | <.0001 |
| Blood Urea Nitrogen (mg/dL) | 32.1 +/− 19.1 (n= 63) | 23.9 +/− 14.8 (n= 45) | 0.02 |
| Sodium (mEq/L) | 139.1 +/− 7.9 (n= 63) | 140.5 +/− 7.7 (n= 45) | 0.4 |
| Potassium (mEq/L) | 3.8 +/− 0.7 (n= 63) | 3.8 +/− 0.7 (n= 45) | 0.5 |
| Aspartate Aminotransferase (u/L) | 123.4 +/− 275.3 (n= 57) | 332.9 +/− 1503.1 (n= 44) | 0.3 |
| Alanine Aminotransferase (u/L) | 87.2 +/− 259.9 (n= 57) | 307.6 +/− 1325.1 (n= 44) | 0.2 |
| Brain Natriuretic Peptide (pg/mL) | 2051.2 +/− 1668.3 (n= 27) | 1914.2 +/− 1853.6 (n= 17) | 0.8 |
| Pro Brain Natriuretic Peptide (pg/mL) | 13389 +/− 12327 (n= 9) | 12237 +/− 15848 (n= 10) | 0.9 |
| Albumin (g/dL) | 3.3 +/− 0.9 (n= 61) | 3.5 +/− 0.7 (n= 43) | 0.2 |
| Pre-Albumin (mg/L) | 153.0 +/− 54.9 (n= 14) | 175.5 +/− 108.0 (n= 13) | 0.5 |
| White Blood Cell Count (x103/μL) | 11.3 +/− 3.5 (n= 62) | 13.0 +/− 9.3 (n= 45) | 0.2 |
| Hemoglobin (g/L) | 136.0 +/− 18.7 (n= 63) | 116.4 +/− 19.3 (n= 45) | <.0001 |
| Platelet Count (x103/gL) | 218.4 +/− 126.8 (n= 62) | 174.1 +/− 92.1 (n= 45) | 0.05 |
| INR (international units) | 1.9 +/− 1.1 (n= 52) | 1.3 +/− 0.3 (n= 44) | 0.001 |
| Uric Acid (mg/dL) | 7.7 +/− 3.1 (n= 11) | 7.1 +/− 5.1 (n= 9) | 0.8 |
| Lymphocyte Count (%) | 18.6 +/− 13.7 (n= 42) | 15.5 +/− 11.0 (n= 37) | 0.3 |
| Creatinine (mg/dL) | 0.6 +/− 0.5 (n= 63) | 0.6 +/− 0.4 (n= 45) | 1.0 |
| eGFR (mL/min/1.73m2) | 74.7 +/− 34.9 (n= 61) | 96.4 +/− 42.5 (n= 45) | 0.005 |
| Bilirubin (mg/dL) | 2.9 +/− 4.1 (n= 55) | 2.9 +/− 5.9 (n= 40) | 1.0 |
| Previous Cardiac Operation | 61 (96.8) | 40 (88.9) | 0.1 |
| Previous ECMO | 10 (15.9) | 12 (26.7) | 0.2 |
| Previous MCSD | 2 (3.2) | 2 (4.4) | 0.7 |
| Patient Profile | 0.2 | ||
| 1. Critical Cardiogenic Shock | 23 (37.1) | 17 (38.6) | |
| 2. Progressive Decline | 33 (53.2) | 19 (43.2) | |
| 3. Stable but Inotrope Dependent | 6 (9.7) | 5 (11.4) | |
| 4.−7. Resting Symptoms or Less Sick | 3 (6.8) | ||
| Pre-Implant Device Strategy | 0. 3 | ||
| Bridge to Transplant - Listed | 37 (58.7) | 21 (46.7) | |
| Bridge to Candidacy | 15 (23.8) | 18 (40.0) | |
| Destination Therapy | 1 (1.6) | ||
| Bridge to Recovery | 6 (9.5) | 5 (11.1) | |
| Other | 4 (6.3) | 1 (2.2) | |
| Device Classification | 0.003 | ||
| Implantable Continuous | 13 (20.6) | 17 (37.8) | |
| Paracorporeal Continuous | 32 (50.8) | 7 (15.6) | |
| Paracorporeal Pulsatile | 15 (23.8) | 15 (33.3) | |
| Percutaneous | 3 (4.8) | 4 (8.9) | |
| TAH | 2 (4.4) | ||
| Pre-Implant Device Type | 0.0004 | ||
| LVAD | 62 (98.4) | 33 (73.3) | |
| BiVAD | 1 (1.6) | 10 (22.2) | |
| TAH | 2 (4.4) |
eGFR = Estimated Glomerular Filtration Rate; ECMO = Extracorporeal Membrane Oxygenation; MCSD = Mechanical Circulatory Support Device; TAH = Total Artifical Heart; LVAD = Left Ventricular Assist Device; BiVAD = Biventricular Assist Device;